

The American Journal of Human Genetics, Volume 89

## Supplemental Data

**Biallelic Mutations in *PLA2G5*,**

**Encoding Group V Phospholipase A<sub>2</sub>,**

**Cause Benign Fleck Retina**

**Panagiotis I. Sergouniotis, Alice E. Davidson, Donna S. Mackay, Eva Lenassi, Zheng Li, Anthony G. Robson, Xu Yang, Jaimie Hoh Kam, Timothy W. Isaacs, Graham E. Holder, Glen Jeffery, Jonathan A. Beck, Anthony T. Moore, Vincent Plagnol, and Andrew R. Webster**

Figure S1. Multiple Alignment of Nine Mammalian *PLA2G5* Orthologs

<i>Homo sapiens</i>	MKGLLPLAWF	LACSVPAVQG	GLLDLKSMIE	KVTGKNALTN	YGFYGCYCGW	GGRGTPKDGT
<i>Pan troglodytes</i>	MKGLLPLAWF	LACSVPAVQG	GLLDLKSMIE	KVTGKNALTN	YGFYGCYCGW	GGRGTPKDGT
<i>Callithrix jacchus</i>	MKGLLPLAWF	LACSVPAVQG	GLLDLKSMIE	KVTGKNALKN	YGFYGCYCGW	GGHGTPKDGT
<i>Bos taurus</i>	MKGLLMLAWF	LACSVPAVPG	SLLDLKSMIE	KVTGKPALKY	YGFYGCYCGW	GGHGTPMDGT
<i>Canis familiaris</i>	MNGLLTLAWL	LACCVRAVPG	GLLDLKSMIE	KVTGKSALTN	YGFYGCYCGW	GGRGTPKDGT
<i>Mus musculus</i>	MKGLLTLAWF	LACSVPAVPG	GLLELKSMIE	KVTRKNAFKN	YGFYGCYCGW	GGRGTPKDGT
<i>Rattus norvegicus</i>	MKRLTLAWF	LACSVPAVPG	GLLELKSMIE	KVTGKNAVKN	YGFYGCYCGW	GGHGTPKDGT
<i>Oryctolagus cuniculus</i>	MKGLLTLAWF	LACGVPVAVPG	SLLDLKSMIE	KVTGKNALTN	YGFYGCYCGW	GGRGTPMDGT
<i>Pteropus vampyrus</i>	MKSLTLAWF	LACSVPTVPG	GLLELKSMIK	TVTGKNALIN	YGFYGCYCGW	GGHGTPKDGT
	..... .....	..... .....	..... .....	..... .....	..... .....	..... .....
	65	75	85	95	105	115
<i>Homo sapiens</i>	DWCCWAHDHC	YGRLEEKGCN	IRTQSYKYRF	AWGVVTCEPG	PFCHVNLACAC	DRKLVYCLKR
<i>Pan troglodytes</i>	DWCCWAHDHC	YGRLEEKGCN	IRTQSYKYRF	AWGVVTCEPG	PFCHVKLCAC	DRKLVYCLKR
<i>Callithrix jacchus</i>	DWCCWVHDHC	YGRLEEKGCN	IWTQSYKYRF	AWGLVTCEPG	SFCRVQLCAC	DRKLVYCLKR
<i>Bos taurus</i>	DWCCWKHDHC	YAQMETQDCD	VLTQAYRYRV	AWGFIICEHG	SRCQQQLCAC	DQKFVYCLKR
<i>Canis familiaris</i>	DWCCWVHDRC	YGRLEEKGCN	IRTQSYKYRF	AQGLVTCEYG	PLCQMQLCTC	DRKLVYCLKR
<i>Mus musculus</i>	DWCCQMHDRC	YGQLEEKDCA	IRTQSYDYRY	TNGLVICEHD	SFCPMRLCAC	DRKLVYCLRR
<i>Rattus norvegicus</i>	DWCCRMHDRC	YGLLEEKHCA	IRTQSYDYRF	TQDLVICEHD	SFCPVRLCAC	DRKLVYCLRR
<i>Oryctolagus cuniculus</i>	DWCCWVHDKC	YGRLEERACN	IRTQSYKYRF	ARGLVTCELG	SLCQMLLCTC	DRKFVYCLKR
<i>Pteropus vampyrus</i>	DWCCWVHDRC	YEWLEEKGCY	YRTQSYKYRV	TRGLVTCELG	PLCQVELCAC	DRKLVYCLNR
	..... .....	..... .....				
	125	135				
<i>Homo sapiens</i>	NLRSYNPQYQ	YFPNILCS				
<i>Pan troglodytes</i>	NLRSYNPQYQ	YFPNILCS				
<i>Callithrix jacchus</i>	NLWSYNPRYQ	YFPNILCF				
<i>Bos taurus</i>	NMRSYNPLYQ	YFPNFLCT				
<i>Canis familiaris</i>	NLRSYNPHYQ	YFPNILCS				
<i>Mus musculus</i>	NLWTYNPLYQ	YYPNFLC-				
<i>Rattus norvegicus</i>	NLWSYNRLYQ	YYPNFLC-				
<i>Oryctolagus cuniculus</i>	NLWSYNPHYR	YYPNFFCT				
<i>Pteropus vampyrus</i>	NLRSYNPGYR	FFPNIFCT				


The alignment is numbered in accordance with *Homo sapiens* group V phospholipase A<sub>2</sub> sequence (ENST00000375108). The positions of mutated residues, Gly45 (c.133 G>T, p.Gly45Cys in families J and M) and Gly49 (c.145 G>A, p.Gly49Ser in family L), are highlighted in bold white font. The position of the Ca<sup>2+</sup> binding loop and active site are highlighted in grey consecutively. The PLA2G5 protein is evolutionarily the newest secreted phospholipase A<sub>2</sub> family member; *PLA2G5* orthologs have only been identified in mammals.<sup>11</sup> The alignment was performed with ClustalW using the following Ensembl transcripts: *Homo sapiens*, ENST00000375108; *Pan troglodytes*, ENSPTRT00000000558; *Callithrix jacchus*, ENSCJAT00000054887; *Bos Taurus*, ENSBTAT00000052261; *Canis familiaris*, ENSCAFT00000023974; *Mus musculus*, ENSMUST00000102511; *Rattus norvegicus*, ENSRNOT00000022716; *Oryctolagus cuniculus*, ENSOCUT00000008354; *Pteropus vampyrus*, ENSPVAT00000011947.

Figure S2. Multiple Alignment of Conventional Secreted Phospholipase A<sub>2</sub> Proteins (Groups I/II/V/X) around Residues Mutated in Patients with Benign Fleck Retina

Group V PLA <sub>2</sub>	LKSMIEK-VT	GKNALTNYGF	<b>YG</b> <b>CY</b> <b>C</b> <b>G</b> WGGR	GTPKDGTDWC	CWAHDHCYGR
Group IB PLA <sub>2</sub>	FRKMIKCVIP	GSDPFLEYNN	<b>YG</b> <b>CY</b> <b>C</b> <b>G</b> LGGS	GTPVDELDKC	CQTHDNCYDQ
Group IIA PLA <sub>2</sub>	FHRMIKL-TT	GKEAALS YGF	<b>YG</b> <b>CH</b> <b>C</b> <b>G</b> VGGR	GSPKDATDRC	CVTHDCCYKR
Group IIC PLA <sub>2</sub>	FQRRVKH-IT	GRSAFFSYYG	<b>YG</b> <b>CY</b> <b>C</b> <b>G</b> LGDK	GIPVDDTDRH	SPSSPSPYEK
Group IID PLA <sub>2</sub>	LNKMVKQ-VT	GKMPILSYWP	<b>YG</b> <b>CH</b> <b>C</b> <b>G</b> LGGR	GQPKDATDWC	CQTHDCCYDH
Group IIE PLA <sub>2</sub>	FGVMIEK-MT	GKS-ALQYND	<b>YG</b> <b>CY</b> <b>C</b> <b>G</b> IGGS	HWPVDQTDWC	CHAHDCCYGR
Group IIF PLA <sub>2</sub>	LKAMVEA-VT	GRSAILS FVG	<b>YG</b> <b>CY</b> <b>C</b> <b>G</b> LGGR	GQPKDEV DWC	CHAHDCCYQE
Group X PLA <sub>2</sub>	LAGTVG--CV	GPRTPIAYMK	<b>YG</b> <b>C</b> <b>F</b> <b>C</b> <b>G</b> LGGH	GQPRDAIDWC	CHGHDCCYTR

Mutated group V phospholipase A<sub>2</sub> (PLA<sub>2</sub>) amino acid residues, Gly45 (c.133 G>T, p.Gly45Cys in families J and M) and Gly49 (c.145 G>A, p.Gly49Ser in family L), are highlighted in bold white font. The position of the Ca<sup>2+</sup> binding loop and active site are highlighted in grey consecutively. The alignment was performed with ClustalW using the following Ensembl transcripts: group IB PLA<sub>2</sub>, ENST00000308366; group IIA PLA<sub>2</sub>, ENST00000375111; group IIC PLA<sub>2</sub>, ENST00000429261; group IID PLA<sub>2</sub>, ENST00000375105; group IIE PLA<sub>2</sub>, ENST00000375116; group IIF PLA<sub>2</sub>, ENST00000375102; group V PLA<sub>2</sub>, ENST00000375108; group X PLA<sub>2</sub>, ENST00000438167.

Figure S3. Reverse Transcriptase Polymerase Chain Reactions (RT-PCR) Analysis of *PLA2G5* Expression



A series of reverse transcriptase polymerase chain reactions (RT-PCR) reactions were performed to assess whether the variant identified in subject K-2, c.185G>A, affects pre-mRNA splicing of the *PLA2G5* transcript *in vivo*. Leukocyte RNA was extracted from whole blood samples collected from patient K-2 and a control sample using a QIAamp RNA blood extraction kit (Qiagen, Crawley, UK) according to the manufacturer's guidelines. cDNA was reverse-transcribed using a cDNA synthesis kit (BioLine, London, UK) with random

hexamer primer mix. RT-PCR reactions were performed using primers and condition listed in Table S4.

A. *PLA2G5* was amplified between exons 3 and 5 using primers RT\_F1 and RT\_R1 (top gel) and primers RT\_F2 and RT\_R2 (middle gel). For both reactions two alternative *PLA2G5* amplicons were detected. The lower bands for each reaction represent the expected segment of protein coding *PLA2G5* transcript (240 bp and 346 bp respectively; Ensembl transcript ENST00000375108). The upper bands represent a segment of a transcript containing an additional alternatively spliced 77 bp exon between exons 3 and 4, previously detected in a non-coding *PLA2G5* transcript (317 bp and 423 bp respectively; Ensembl transcript ENST00000478803). The relative abundance of the two amplicons between PS and CS are consistently different in both reactions; the alternatively spliced exon is detected at a higher level in the PS. A schematic representation of the alternatively spliced products detected is given on the right. The house keeping gene,  $\beta$ -*actin* was also amplified as a positive loading control (bottom gel).

B. Schematic representation of *PLA2G5* protein coding transcript ENST00000375108 and non-coding transcript ENST00000478803. The positions of the *PLA2G5* RT-PCR primers used are highlighted. Nucleotide sequence surrounding the alternatively spliced *PLA2G5* intron-exon boundaries are shown (transcribed sequence in capital, translated sequence in bold font). The position of the mutated nucleotide identified in patient K-2 (c.185 G>A, p.Trp62X) is highlighted in red.

PS, patient sample; CS, control sample; NTC, no template control.

Table S1. Segments of Homozygosity Yielded from Homozygosity Mapping in Families J and K

<b>Chromosome</b>	<b>From</b>	<b>To</b>	<b>Genetic Distance</b> (Marshfield linkage map)	<b>Reference</b>
chr1	54,742,471 (rs590041)	64,361,979 (rs855824)	19 cM	Family J, regions > 1 cM
chr2	232,025,284 (rs6437002)	236,731,624 (rs952608)	14 cM	
chr1	20,238,860 (rs3738122)	23,266,939 (rs1832047)	5 cM	
chr7	pter	8,546,068 (rs2189903)	15 cM	Family K, regions > 10 cM
chr18	pter	4,925,739 (rs9961128)	12 cM	
chr1	18,477,450 (rs10796459)	24,578,011 (rs12407356)	12 cM	
chr1	110,701,174 (rs12118197)	144,989,739 (rs2590125)	11 cM	

Genotypes of subjects J-1, J-2, J-3, J-4, J-5, and J-6 were generated using the Genechip Human Mapping 50K Xba Array (Affymetrix, Santa Clara, CA, USA). Genotypes of subject K-2 were generated using the Affymetrix Genome-Wide Human SNP Array 6.0.

Table S2. Primer Sequences and Conditions used for *PLA2G5* Mutation Screening

Primer	Sequence (5'-3')	Optimised annealing temperature (°C) <sup>a</sup>	Amplicon size (bp)
exon 2F exon 2R	TGACGGGGAGTGGGAATAGATGGG TCTCTACGACCTCAATGGCTGGTGT	68	203
exon 3F exon 3R	TTGCACCTCCCTTCCCCTAAT TACTCATCTTCCAGAACTGATATGG	68	343
exon 4F exon 4R	ACACTACCAGATCCTCCCTGCCA TTCTGCACCCAACTCCTCCTC	68	319
exon 5F exon 5R	AGTCCATGGGGTCTCTGCTG AAAGAGGCACCAGCGATCCC	68	681

<sup>a</sup>Polymerase chain reactions (PCRs) were performed in a 12.5 µl volume containing 1 Unit Taq polymerase (BIOTAQ DNA Polymerase, Bioline, London, UK). The thermal cycling profile for all reactions was: initial denaturation (94°C for 2 minutes), amplification (35 cycles of: 94°C denaturation for 30 seconds, \*\* °C annealing for 30 seconds, 72°C extension for 30 seconds) and final extension (72 °C for 7 minutes).



Table S3. Summary of Coding *PLA2G5* Sequence Variants Identified Here and Elsewhere

Coding DNA variants		SIFT		Polyphen 2		Blosum 62 score (-4 to 11)	Reference (observed allele count)
Nucleotide	Protein	Prediction	Tolerance index (0 to 1)	Prediction	HumVar Score (0 to 1)		
c.9 C>T	p.(=)	not applicable				6	1000G [rs2020887], EVS (1244/3632), this study
c.15 C>G	p.(=)	not applicable				4	EVS (1/4877)
c.48 T>C	p.(=)	not applicable				7	EVS (1/4877)
c.88 G>A	p.Glu30Lys	tolerated	0.78	Benign	0.03	1	EVS (1/4877)
c.102 G>T	p.(=)	not applicable				6	Bushman_pop [rs111762734]
c.108 C>T	p.(=)	not applicable				6	internal db (1/448), EVS (3/4875)
c.110 C>G	p.Ala37Gly	tolerated	0.35	PRD	0.97	0	EVS (1/4877)
<b>c.133 G&gt;T</b>	<b>p.Gly45Cys</b>	intolerant	0.00	PRD	1.00	-3	this study [families J and M]
c.144 C>T	p.(=)	not applicable				9	1000G [rs11573265], EVS (77/4801), this study
<b>c.145 G&gt;A</b>	<b>p.Gly49Ser</b>	intolerant	0.02	PRD	1.00	0	this study [family L]
<b>c.157 C&gt;T</b>	<b>p.Arg53X</b>	not applicable				-4	this study [family L]
c.181 G>A	p.Asp61Asn	intolerant	0.01	PRD	1.00	1	EVS (1/4877)
<b>c.185 G&gt;A</b>	<b>p.Trp62X</b>	not applicable				-4	this study [family K]
c.292 G>A	p.Glu98Lys	intolerant	0.04	Benign	0.47	1	EVS (1/4855)
c.297 C>T	p.(=)	not applicable				6	EVS (2/4876)
c.311 A>C	p.His104Pro	tolerated	0.23	Benign	0.00	-2	EVS (1/4877)
c.312 T>C	p.(=)	not applicable				8	internal db (1/448), EVS (7/4871)
c.368 G>A	p.Arg123Gln	tolerated	0.53	Benign	0.10	1	EVS (2/4876)
<b>c.383delA</b>	<b>p.Gln128ArgfsX88</b>	not applicable				-4	this study [family M]
c.402 C>T	p.(=)	not applicable				6	Bushman_pop [rs112000348]
c.406 C>T	p.Leu136Phe	tolerated	0.71	Benign	0.00	0	EVS (1/4877)

SIFT (v4.0.4) results are reported to be tolerant if tolerance index  $\geq 0.05$  or intolerant if tolerance index  $< 0.05$ . Polyphen-2 (v2.1.0r367) appraises mutations qualitatively as Benign, Possibly Damaging or Probably Damaging (PRD) based on the model's false positive rate. Blosum62 substitution matrix score positive numbers indicate a substitution more likely to be tolerated evolutionarily and negative numbers suggest the opposite. The cDNA is numbered according to Ensembl transcript ID ENST00000375108, in which +1 is the A of the translation start codon. Novel changes are in bold font.

EVS denotes variants in the Exome Variant Server, NHLBI Exome Sequencing Project, Seattle, WA, USA [accessed 13/09/2011]. 1000G represents variants identified in the 20101123 sequence and alignment release of the 1000 genomes project (1094 genomes). Bushman\_pop denotes variants identified only among the four Bushmen genomes sequenced by Schuster *et al.*<sup>46</sup> Our internal db contains data from 224 exomes (cases with neurodegenerative disease).

Table S4. Primer Sequences and Conditions Used for Reverse Transcriptase Polymerase Chain Reactions (RT-PCRs)

Primer	Sequence (5'-3')	Optimised annealing temperature (°C) <sup>a</sup>	Amplicon size (bp)
PLA2G5_RT_F1 PLA2G5_RT_R1	CCCTGACAAACTACGGCTTC AGTAGACGAGCTTCCGGTCA	62	240 <sup>b</sup> /317 <sup>c</sup>
PLA2G5_RT_F2 PLA2G5_RT_R2	GAGGCTTGCTGGACCTAAAA GAGGCCTAGGAGCAGAGGAT	62	346 <sup>b</sup> /423 <sup>c</sup>
$\beta$ -actin_RT_F $\beta$ -actin_RT_R	CTGGGACGACATGGAGAAAA AAGGAAGGCTGGAAGAGTGC	60	564

<sup>a</sup>Reverse transcriptase polymerase chain reactions (RT-PCRs) were performed in a 25  $\mu$ l volume containing 2 Units Taq polymerase (BIOTAQ DNA Polymerase, Bioline, London, UK). The thermal cycling profile for all reactions was: initial denaturation (94°C for 2 minutes), amplification (up to 40 cycles of: 94°C denaturation for 30 seconds, \*\* °C annealing for 30 seconds, 72°C extension for 45 seconds) and final extension (72 °C for 7 minutes).

<sup>b</sup>size of PCR amplimer when amplifying Ensembl transcript ENST00000375108.

<sup>c</sup>size of PCR amplimer when amplifying Ensembl transcript ENST00000478803 containing an alternatively spliced 77 bp exon.